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Low molecular weight heparins (LMWHs) are recognised as the preferred anticoagulants in the prevention and treatment of venous thromboembolism. Anti-Factor Xa (anti-FXa) levels are used to monitor the anticoagulant effect of LMWHs and such assays are routinely employed in hospital diagnostic laboratories. In this study, a fluorogenic anti-FXa assay was developed using a commercially available fluorogenic substrate with an attached 6-amino-1naphthalene-sulfonamide (ANSN) fluorophore and was used for the determination of two LMWHs, enoxaparin and tinzaparin and the heparinoid, danaparoid. The assay was based on the complexation of heparinised plasma with 100 nM exogenous FXa and 25 µM of the fluorogenic substrate Mes-D-
LGR-ANSN (C 2 H 5 ) 2 (SN-7). The assay was tested with pooled plasma samples spiked with anticoagulant concentrations in the range 0-1.6 U mL −1 . The statistically sensitive assay range was 0-0.4 U mL −1 for enoxaparin and tinzaparin and 0-0.2 U mL −1 for danaparoid, with assay variation typically below 10.5%. This assay was then compared with a previously published fluorogenic anti-FXa assay developed with the peptide substrate, methylsulfonyl-d-cyclohexylalanyl-glycyl-arginine-7-amino-4-methylcoumarin acetate (Pefafluor FXa). Both assays were compared in terms of fluorescence intensity, lag times and sensitivity to anticoagulants. Initially, chromogenic substrates based on the chromophore 69 p-nitroaniline were developed for thrombin, plasmin, and 70 trypsin analysis [8, 10] , followed by the development of 71 assays using fluorogenic substrates for thrombin [11, 12] .
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Once the specific peptide cleavage sequence was known, 73 these developments were rapidly extended to other coagu- were performed with 10 mM HEPES. detecting groups namely ANSN [9] and AMC [14] . Harris et al. [16] in the presence and absence of two 439 LMWHs (i.e., enoxaparin and tinzaparin) and danaparoid.
440
The principle of the assay is to measure the rate of between 5% and 10% [16] .
Pefafluor FXa has a relatively high K m of 220 μM t3.1 it is more precise than the ANSN-based fluorogenic anti-
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FXa assay examined in this study. No Query.
